Here's Why Quest Diagnostics (DGX) is a Strong Value Stock

Quest Diagnostics (DGX) is highlighted as a strong value stock by Zacks, despite its #3 (Hold) rank, due to its B-rated Value and overall VGM Style Scores and an attractive forward P/E of 18.97. The diagnostic services provider has seen positive analyst sentiment, with three upward revisions to its fiscal 2025 earnings estimates in the last 60 days, increasing the consensus to $9.74 per share, alongside a historical average earnings surprise of +2.1%. These metrics suggest DGX warrants consideration for investors seeking value, despite its current Zacks Hold rating.

Analysis

Quest Diagnostics (DGX) presents a nuanced investment case, characterized by a neutral Zacks #3 (Hold) rating counterbalanced by strong underlying value characteristics. The stock's appeal to value investors is supported by a 'B' grade in both the Value and overall VGM Style Scores, anchored by an attractive forward P/E ratio of 18.97. Positive sentiment from the analyst community is evident, with three upward earnings estimate revisions for fiscal 2025 within the last 60 days, nudging the consensus EPS estimate to $9.74. Furthermore, the company has demonstrated a consistent ability to outperform expectations, reflected in an average historical earnings surprise of +2.1%. While the 'Hold' rating may temper expectations for immediate, sharp upside, the combination of favorable valuation metrics and positive earnings estimate trends suggests the stock warrants consideration for a value-focused portfolio.

Key Decisions for Investors

• Value-focused investors should consider DGX a candidate for their watchlist, given its attractive forward P/E of 18.97 and favorable 'B' Value Score.
• The neutral Zacks #3 'Hold' rating implies that patience may be required, as the analysis does not point to immediate, significant catalysts for near-term price appreciation.
• Investors should monitor future analyst earnings revisions for fiscal 2025, as continued upward momentum could serve as a leading indicator for a potential re-rating of the stock.
• Given the mixed signals of a 'Hold' rank alongside positive value metrics, a prudent approach could be to consider a partial position rather than a full allocation until more definitive buy signals emerge.